Immunonutrition Supplementation in Head and Neck Cancer Patients Undergoing Cancer Treatment Study

Inclusion Criteria: * Written informed consent obtained * Adult HNC patients, male or female, above 18 years of age * Primary HNC diagnosis, stage I to III; including: cancer of the nasopharynx, oropharynx, oral cavity, hypopharynx, or larynx, etc. * Referred and planned for curative-intent cancer treatment (radiotherapy and chemotherapy) * Eastern Cooperative Oncology Group (ECOG) performance status \< 2 Exclusion Criteria: * Inability or unwillingness to provide written informed consent or comply with the requirements of the protocol * Patients with metastatic stage or recurring/relapse of cancer at same site * Planned for palliative cancer treatment * Underlying severe hepatic failure or renal dysfunction (eGFR \< 30ml/min/1.73m2) * Underlying severe sepsis, neutropenia, immune-deficiencies or autoimmune diseases * Consumption of supplements or enriched foods containing immunonutrients (omega- 3, arginine or nucleotides) in the previous month prior to study; including dietary supplements such as: fish oil capsules, arginine tablets/powder, RNA capsules, etc. * Known allergy or intolerance to components of the immunonutrition supplement (cow's milk, fish or soy) * Enrolment in other cancer treatment trials